Document is current
Any future updates will be listed below
-
Authors
Sedaghat-Hamedani, Farbod https://orcid.org/0000-0002-3266-0527
Zema, Carla L.
Schultze, Michael https://orcid.org/0009-0002-1494-5446
Garcia, Tarcyane B. https://orcid.org/0000-0002-2038-1395
Kossack, Nils https://orcid.org/0000-0002-9521-3898
Borchert, Julia
Maksabedian Hernandez, Ervant J. https://orcid.org/0000-0003-1945-3061
Zhong, Yue
Bluhmki, Tobias https://orcid.org/0000-0003-2625-4167
Krause, Taryn https://orcid.org/0009-0009-5681-8497
Schmoelders, Johanna
Meder, Benjamin https://orcid.org/0000-0003-0741-2633
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 28 September 2025
First Online: 27 October 2025
Declarations
:
: FS-H has received travel support and speaker honoraria from Bristol Myers Squibb; has served as a scientific adviser for Bristol Myers Squibb; and has engaged in the planning and execution of clinical trials for mavacamten. CLZ was a contractor for Bristol Myers Squibb at the time the study was conducted. MS is an employee of ZEG Berlin, which received funding from Bristol Myers Squibb to conduct this study. TBG, NK, and JB are employees of WIG2 GmbH, which received funding from Bristol Myers Squibb to conduct this study. EJMH, YZ, TB, and JS are employees of Bristol Myers Squibb and may own stock in Bristol Myers Squibb. TK was an employee of Bristol Myers Squibb at the time the study was conducted. BM has received travel support and speaker honoraria from Bristol Myers Squibb; is engaged in clinical trials sponsored by Bristol Myers Squibb; and has received research funding for a mavacamten registry (TORCHmava).
